IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Peer Comparison
Peer Comparison
Performance
Performance Report
Gland Pharma IPO is a Book Building IPO listing on BSE,NSE exchange, with an ipo size of ₹ 6479.55 Cr. The company is based in Hyderabad and caters to Pharmaceutical sector. Citigroup Global Markets India , Haitong Securities India , Kotak Mahindra Capital Company , Nomura Financial Advisory And Securities (India) are the merchant bankers of Gland Pharma IPO. It is a MainBoard IPO which filed its Draft Red Herring Prospectus (DRHP) on 10th July 2020.
Gland Pharma IPO open date is 9th November 2020 and close date is 11th November 2020. IPO Allotment Date is 17th November 2020 and Listing date is 20th November 2020.
IPO
Size:
₹ 6479.55 Cr.
Avg IPO Size (Sector Based)
: ₹
1,431.30 cr.
Sector: Pharmaceutical
IPO so far:
23
Merchant Banker:
Citigroup Global
IPO by BRLM so far:
72
City:
Hyderabad
IPO so far:
36
Revenue (annualised):
₹
3665.16
cr. 
PE
Ratio:
19.50x
Average Sector PE Ratio: 27.10x
Gland Pharma IPO size is ₹ 6479.55 Cr. with IPO price of ₹ 1500.00. IPO subscription will start on IPO open date and end on IPO close date as per above. IPO valuation metrics can be seen here.
Citigroup Global Markets India Private Limited is the book-running lead manager of the Gland Pharma IPO. Link Intime India Private Limited is the Registrar for Gland Pharma IPO.
Gland Pharma IPO Draft red herring prospectus (DRHP) and Red Herring prospectus (RHP) are available below.
Gland Pharma IPO, based in Hyderabad, operates in the Pharmaceutical sector with a focus on manufactures inject tables. The company is launching its MainBoard IPO on the BSE,NSE exchange, using the Book Building Issue method. Gland Pharma IPO size is ₹ 6479.55 Cr. with fresh issue size of ₹ 1,250 and Offer for sale being ₹ 5229.55 Cr.
The IPO allotment date for Gland Pharma IPO is expected to be 17th November 2020, after the finalization of basis of allotment. Investors can check Gland Pharma IPO allotment status on the registrars website, Link Intime India Private Limited . Gland Pharma IPO refund dates are 18th November 2020.
Gland Pharma IPO is expected to be listed on 20th November 2020.
The upper price band for the Gland Pharma IPO is set at ₹ 1500.00 per equity share. IPO price band is arrived at on the basis of IPO Valuation (P/E multiple) which is mentioned in the RHP.
For IPO analysis on Gland Pharma IPO, explore our Financial Review Page for insights on fundamentals, peer analysis, and key IPO data, assisting investors to make informed decisions to apply or not.
To apply for the Gland Pharma IPO, investors can use the ASBA (Application Supported by Blocked Amount) process via their bank's net banking or apply through UPI using a registered broker or trading app. The IPO is available in retail, HNI, and institutional investor categories. Investors must select the lot size, enter bid details within the price band, and submit their application before the IPO closing date of 11th November 2020. After submission, funds are blocked until the basis of allotment of Gland Pharma IPO is finalised.
The merchant banker for Gland Pharma IPO is Citigroup Global Markets India Private Limited , Haitong Securities India Private Limited , Kotak Mahindra Capital Company Limited , Nomura Financial Advisory And Securities (India) Private Limited . Citigroup Global Markets India Private Limited , Haitong Securities India Private Limited , Kotak Mahindra Capital Company Limited , Nomura Financial Advisory And Securities (India) Private Limited manages the IPO process, including underwriting, regulatory compliance, and investor coordination. Investors can refer to the Gland Pharma IPO RHP for further details.
The registrar for Gland Pharma IPO is Link Intime India Private Limited . Investors can go to Link Intime India Private Limited registrar website for IPO allotment status, refund processing, and other queries related to Gland Pharma IPO through their official website or helpline.
Gland Pharma IPO was subscribed 2.06 times. Stay updated on IPO details, subscription, and allotment news for informed investment decisions.
IPO
Size:
₹ 6,479.55 Cr.
Avg IPO Size (Sector Based)
:
₹ 1,431.30 Cr.
Sector: Pharmaceutical
IPO so far:
23
Merchant Banker:
Citigroup Global
IPO by BRLM so far:
72
City:
Hyderabad
IPO so far:
36
Revenue (annualised):
₹ 3,536.80 cr.
PE
Ratio:
19.50x
Average Sector PE Ratio: 27.10x
Gland Pharma IPO may offer opportunites, depending on your investment strategy. For in-depth analysis, risk factors, and KPIs, check our detailed report on Gland Pharma Financial Review Page
Merchant Banker(s) of Gland Pharma IPO: Citigroup Global Markets India Private Limited , Haitong Securities India Private Limited , Kotak Mahindra Capital Company Limited , Nomura Financial Advisory And Securities (India) Private Limited
Gland Pharma IPO subscription was 2.06 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Gland Pharma IPO listed at a listing price of 1820.45 against the offer price of 1500.00.
The current market price of Gland Pharma is 2000.30.
Why Us?
